New data on the secondary endpoint shows up to 52.3% of adults with fibrosis stages F1, F2 and F3 had improvement in fibrosis due to MASH
The Gavi Board today approved the Vaccine Alliance's strategy for the five-year period running from 2026 to 2030
This strategic decision will unlock significant value for our scientific and industrial products business
PICCOLO trial met its primary endpoint of objective response rate (ORR)
Updated analysis from Memorial Sloan Kettering Cancer Center presented at ASCO 2024 has expanded to 42 patients with clinical complete response
Scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer and GSK will continue to vigorously defend itself against all claims
Sleep disturbances are among the most frequent and disruptive symptoms associated with menopause which can impact women’s health and quality of life
Seymour is recognized as one of the foremost quality leaders in the pharmaceutical industry
Seymour is recognized as one of the foremost quality leaders in the pharmaceutical industry
Recommendation based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months
Subscribe To Our Newsletter & Stay Updated
